RARidhima Aggarwal

Ridhima Aggarwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ridhima Aggarwal has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Rawat

    Pediatric Allergy and Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    3 shared publications
  • Ankur Kumar Jindal

    Pediatric Clinical Immunology and Rheumatology, Department of Pediatrics Manipal Hospital Bengaluru India

    3 shared publications
  • Deepti Suri

    Pediatric Allergy Immunology Unit, Department of Pediatrics, https://ror.org/009nfym65Postgraduate Institute of Medical Education & Research, Chandigarh, India

    3 shared publications
  • Archan Sil

    Pediatric Allergy Immunology Unit, Department of Pediatrics Post Graduate Institute of Medical Education and Research Chandigarh India

    2 shared publications
  • Manpreet Dhaliwal

    Molecular Immunology, Pediatric Clinical Immunology and Rheumatology, Department of Pediatrics, PGIMER, Chandigarh, India

    2 shared publications
  • Pandiarajan Vignesh

    Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    2 shared publications

Latest Publications

  • Open Access

    Life-threatening hepatic complications in children with ADA-SCID

    by Ridhima Aggarwal, Alison Mansfield, Jinhua Xu-Bayford, Claire Booth, Konstantinos Vazouras

    We describe two cases of ADA-SCID complicated by hepatoblastoma and infantile hepatic hemangiomatosis. We highlight the multidisciplinary management of these severe liver manifestations and the modifications required to deliver definitive corrective therapy, including gene therapy and hematopoietic stem cell transplantation.

  • Open Access

    Large vessel vasculopathy: An underrecognized complication in Wiskott–Aldrich syndrome

    by Deepti Suri, Pallavi L. Nadig, Dev Desai, Yamini Sharma, Ahmed Jamal, Gayathri C. Vaitheeswaran, Himanshi Choudhary, Murugan Sudhakar, Ridhima Aggarwal, Suprit Basu, et al.

    Suri et al. from PGIMER, Chandigarh, India, report large vessel vasculopathy as a rare, life-threatening, and underrecognized complication of Wiskott–Aldrich syndrome, often mimicking Takayasu arteritis. They implicate immune dysregulation, endothelial injury, and viral triggers, emphasizing early vascular screening and timely definitive therapy to reduce high mortality.

  • Tuberculosis and Bacillus Calmette-Guérin Disease in Patients with Chronic Granulomatous Disease: an Experience from a Tertiary Care Center in North India

    by Pandiarajan Vignesh, Archan Sil, Ridhima Aggarwal, Wrik Laha, Sanjib Mondal, Manpreet Dhaliwal, Saniya Sharma, Rakesh Kumar Pilania, Ankur Kumar Jindal, Deepti Suri, et al.

    Chronic granulomatous disease (CGD) is a phagocytic defect characterized by recurrent bacterial and fungal infections. We report clinical profile of patients with CGD and mycobacterial infections in a cohort from North India. A review of clinical and laboratory records was carried out for patients with CGD registered at our center between 1990 and 2021. Of the 99 patients with CGD, 22 had mycobacterial infections—Mycobacterium tuberculosis and M. bovis-BCG in 11 each. Among the children with M. bovis-BCG infection, 6 had localized and 5 had disseminated BCG disease. Median age at onset of symptoms and diagnosis of BCG disease was 5 months and 15 months, respectively. While disseminated forms of BCG were noted only in CYBB defect, none of the patients with NCF1 defect developed complications due to BCG vaccine. A recurring radiological feature was left axillary lymph node calcification, which was present in around 50% of CGD patients with BCG infections. Of 11 patients with tuberculosis, pulmonary, pleuro-pulmonary, abdominal, and disseminated forms were present in 6, 1, 2, and 2, respectively. Median age at onset of symptoms and diagnosis of tuberculosis was 129 months and 130 months, respectively. Molecular defects were identified in CYBB (5), NCF1 (4), and CYBA (1). Incidence of tuberculosis and BCG-related complications in patients with CGD is higher than the normal population. Screening for CGD is warranted in any patient with adverse reactions to BCG vaccination, calcification of left axillary lymph node, and persistent, recurrent or disseminated forms of tuberculosis.


  • Open Access

    Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent

    by Ankur Kumar Jindal, Archan Sil, Ridhima Aggarwal, Keshavamurthy Vinay, Anuradha Bishnoi, Deepti Suri, Amit Rawat, Muthu Sendhil Kumaran, Biman Saikia, Rashmi Sarkar, et al.

    Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.